Three Healthcare Stocks in Focus: Regulatory Milestones and Strategic Moves

Alembic Pharmaceuticals cleared a critical USFDA inspection at its Panelav API facilities, receiving an Establishment Inspection Report for the late-May audit. The regulatory green light strengthens the company's position in the US generics market.

Apollo Hospitals Enterprises makes a bold Rs 1,254 crore play to consolidate control of its subsidiary AHLL, buying out IFC's 31% stake. Simultaneously, the healthcare giant commits Rs 573 crore to build a state-of-the-art oncology center in Gurugram, signaling aggressive expansion in specialized care.

Dr. Reddy's Laboratories faces regulatory hurdles after its Hyderabad biologics plant received five FDA observations during a September pre-approval inspection. The company maintains confidence in addressing the issues within mandated timelines, crucial for its biosimilar pipeline.